- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Chemotherapy-Induced Nausea and Vomiting (CINV) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Chemotherapy-Induced Nausea and Vomiting (CINV) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Chemotherapy-Induced Nausea and Vomiting (CINV) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CINV segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chemotherapy-Induced Nausea and Vomiting (CINV) include Merck, Eisai, ProStrakan, Helsinn Holding, and Mundipharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chemotherapy-Induced Nausea and Vomiting (CINV) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CINV
PONV
Market segment by Application, can be divided into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Market segment by players, this report covers
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chemotherapy-Induced Nausea and Vomiting (CINV) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chemotherapy-Induced Nausea and Vomiting (CINV), with revenue, gross margin and global market share of Chemotherapy-Induced Nausea and Vomiting (CINV) from 2019 to 2022.
Chapter 3, the Chemotherapy-Induced Nausea and Vomiting (CINV) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chemotherapy-Induced Nausea and Vomiting (CINV) market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chemotherapy-Induced Nausea and Vomiting (CINV) research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Chemotherapy-Induced Nausea and Vomiting (CINV)
1.2 Classification of Chemotherapy-Induced Nausea and Vomiting (CINV) by Type
1.2.1 Overview: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Type in 2021
1.2.3 CINV
1.2.4 PONV
1.3 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market by Application
1.3.1 Overview: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size & Forecast
1.5 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast by Region
1.5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region, (2017-2022)
1.5.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
1.5.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
1.5.6 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
1.6.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
1.6.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.1.4 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Merck Recent Developments and Future Plans
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.2.4 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Eisai Recent Developments and Future Plans
2.3 ProStrakan
2.3.1 ProStrakan Details
2.3.2 ProStrakan Major Business
2.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.3.4 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 ProStrakan Recent Developments and Future Plans
2.4 Helsinn Holding
2.4.1 Helsinn Holding Details
2.4.2 Helsinn Holding Major Business
2.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.4.4 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Helsinn Holding Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.5.4 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 Qilu Pharma
2.6.1 Qilu Pharma Details
2.6.2 Qilu Pharma Major Business
2.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.6.4 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Qilu Pharma Recent Developments and Future Plans
2.7 Teva
2.7.1 Teva Details
2.7.2 Teva Major Business
2.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.7.4 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Teva Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.8.4 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Heron Therapeutics
2.9.1 Heron Therapeutics Details
2.9.2 Heron Therapeutics Major Business
2.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.9.4 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Heron Therapeutics Recent Developments and Future Plans
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business
2.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.10.4 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Roche Recent Developments and Future Plans
2.11 Mylan
2.11.1 Mylan Details
2.11.2 Mylan Major Business
2.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.11.4 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Mylan Recent Developments and Future Plans
2.12 Tesaro
2.12.1 Tesaro Details
2.12.2 Tesaro Major Business
2.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
2.12.4 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Tesaro Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Market Share in 2021
3.2.2 Top 10 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Head Office, Products and Services Provided
3.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Mergers & Acquisitions
3.5 Chemotherapy-Induced Nausea and Vomiting (CINV) New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Market Share by Type (2017-2022)
4.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Application (2017-2022)
5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
6.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
6.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
6.3.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
6.3.2 United States Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
6.3.3 Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
6.3.4 Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
7.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
7.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
7.3.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
7.3.2 Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
7.3.3 France Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
7.3.5 Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
7.3.6 Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
8.2 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
8.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region
8.3.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2017-2028)
8.3.2 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8.3.3 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8.3.4 South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8.3.5 India Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
8.3.7 Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
9.2 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
9.3 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
9.3.1 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
9.3.2 Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
9.3.3 Argentina Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
10.2 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
10.3 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
10.3.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
10.3.2 Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
10.3.4 UAE Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2023-2028)
Table 6. Merck Corporate Information, Head Office, and Major Competitors
Table 7. Merck Major Business
Table 8. Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 9. Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Eisai Corporate Information, Head Office, and Major Competitors
Table 11. Eisai Major Business
Table 12. Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 13. Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. ProStrakan Corporate Information, Head Office, and Major Competitors
Table 15. ProStrakan Major Business
Table 16. ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 17. ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Helsinn Holding Corporate Information, Head Office, and Major Competitors
Table 19. Helsinn Holding Major Business
Table 20. Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 21. Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Mundipharma Corporate Information, Head Office, and Major Competitors
Table 23. Mundipharma Major Business
Table 24. Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 25. Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Qilu Pharma Corporate Information, Head Office, and Major Competitors
Table 27. Qilu Pharma Major Business
Table 28. Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 29. Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Teva Corporate Information, Head Office, and Major Competitors
Table 31. Teva Major Business
Table 32. Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 33. Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 37. Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Heron Therapeutics Corporate Information, Head Office, and Major Competitors
Table 39. Heron Therapeutics Major Business
Table 40. Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 41. Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Roche Corporate Information, Head Office, and Major Competitors
Table 43. Roche Major Business
Table 44. Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 45. Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Mylan Corporate Information, Head Office, and Major Competitors
Table 47. Mylan Major Business
Table 48. Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 49. Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Tesaro Corporate Information, Head Office, and Major Competitors
Table 51. Tesaro Major Business
Table 52. Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
Table 53. Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 55. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 56. Breakdown of Chemotherapy-Induced Nausea and Vomiting (CINV) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Chemotherapy-Induced Nausea and Vomiting (CINV) Players Head Office, Products and Services Provided
Table 58. Chemotherapy-Induced Nausea and Vomiting (CINV) Mergers & Acquisitions in the Past Five Years
Table 59. Chemotherapy-Induced Nausea and Vomiting (CINV) New Entrants and Expansion Plans
Table 60. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Type (2017-2022)
Table 61. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Type (2017-2022)
Table 62. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Forecast by Type (2023-2028)
Table 63. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022)
Table 64. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Forecast by Application (2023-2028)
Table 65. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
Table 66. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
Table 67. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
Table 68. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
Table 69. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
Table 70. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
Table 71. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
Table 72. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
Table 73. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
Table 74. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
Table 75. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
Table 76. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
Table 77. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
Table 78. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
Table 79. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
Table 80. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
Table 81. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2017-2022) & (USD Million)
Table 82. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2023-2028) & (USD Million)
Table 83. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
Table 84. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
Table 85. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
Table 86. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
Table 87. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
Table 88. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
Table 89. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
Table 90. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
Table 91. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
Table 92. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
Table 93. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
Table 94. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chemotherapy-Induced Nausea and Vomiting (CINV) Picture
Figure 2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Type in 2021
Figure 3. CINV
Figure 4. PONV
Figure 5. Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Application in 2021
Figure 6. Hospitals Picture
Figure 7. Ambulatory Surgical Centers Picture
Figure 8. Diagnostic Centers Picture
Figure 9. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2017-2028)
Figure 12. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region in 2021
Figure 13. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
Figure 19. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
Figure 20. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends
Figure 21. Merck Recent Developments and Future Plans
Figure 22. Eisai Recent Developments and Future Plans
Figure 23. ProStrakan Recent Developments and Future Plans
Figure 24. Helsinn Holding Recent Developments and Future Plans
Figure 25. Mundipharma Recent Developments and Future Plans
Figure 26. Qilu Pharma Recent Developments and Future Plans
Figure 27. Teva Recent Developments and Future Plans
Figure 28. Novartis Recent Developments and Future Plans
Figure 29. Heron Therapeutics Recent Developments and Future Plans
Figure 30. Roche Recent Developments and Future Plans
Figure 31. Mylan Recent Developments and Future Plans
Figure 32. Tesaro Recent Developments and Future Plans
Figure 33. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Players in 2021
Figure 34. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share in 2021
Figure 36. Global Top 10 Players Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Type in 2021
Figure 39. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share Forecast by Type (2023-2028)
Figure 40. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Application in 2021
Figure 41. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share Forecast by Application (2023-2028)
Figure 42. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
Figure 43. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
Figure 44. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
Figure 45. United States Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
Figure 49. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
Figure 50. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
Figure 51. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2017-2028)
Figure 59. China Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
Figure 66. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
Figure 67. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
